Lorcaserin for weight management

Figures & data

Table 1 Summary of clinical studies of lorcaserin

Study	Design and intervention	Results	P value	Reference
Fidler et al	Randomized, double-blind, placebo-controlled; lorcaserin 10 mg bid, lorcaserin 10 mg qd, or placebo × 52 weeks	At 52 weeks, weight loss >5% of BBW occurred in 47.2% of lorcaserin 10 mg bid group, 40.2% of lorcaserin 10 mg qd group, and in 25% of placebo subjects	P < 0.0001 for both doses versus placebo	20
Smith et al	Randomized, double-blind, placebo-controlled; lorcaserin 10 mg bid or placebo × 52 weeks; placebo continued for 52 weeks, lorcaserin group randomized in 2:1 ratio to continue lorcaserin 10 mg bid or placebo × 52 weeks	At 52 weeks, weight loss >5% of BBW occurred in 47.5% of lorcaserin 10 mg bid group and 20.3% of placebo subjects	P < 0.001	21
O’Neil et al	Randomized, double-blind, placebo-controlled; lorcaserin 10 mg bid, lorcaserin 10 mg qd, or placebo × 52 weeks	At 52 weeks, weight loss >5% of BBW occurred in 37.5% of lorcaserin 10 mg bid group, 44.7% of lorcaserin 10 mg qd group, and 16.1% of placebo subjects	P < 0.001 for both doses versus placebo	22

Abbreviations: BBW, baseline body weight; bid, twice daily; qd, once daily.

Table 2 Patient satisfaction with lorcaserin

Study	Placebo	Lorcaserin 10 mg twice daily	P value*	Lorcaserin 10 mg once daily	P value*	Reference
BLOSSOM
IWQOL-LITE score (baseline)	75.3 ± 15.6	74.7 ± 16.1		75.5 ± 16.0		20
Change from baseline	10.0 ± 10.1	11.8 ± 10.1	<0.001	11.3 ± 10.3	<0.001
BLOSSOM per-protocol population
IWQOL-LITE score (baseline)	76.4 ± 14.9	74.6 ± 15.9		76.4 ± 15.5		20
Change from baseline	10.4 ± 9.9	12.2 ± 9.8	<0.001	12.6 ± 9.8	<0.001
BDI-II score	4.2 ± 0.1	4.2 ± 0.1
Change from baseline	−0.9 ± 0.1	−1.1 ± 0.1	0.26
BLOOM ITT/LOCF
IWQOL-LITE score (baseline)	73.85 ± 0.42	73.92 ± 0.41		N/A	N/A	21
Change from baseline	10.7 ± 0.4	12.4 ± 0.4	<0.001	N/A	N/A
BLOOM repeated-measures analysis
IWQOL-LITE score (baseline)	73.85 ± 0.42	73.92 ± 0.41		N/A	N/A	21
Change from baseline	10.6 ± 0.2	12.4 ± 0.2	<0.001	N/A	N/A
IWQOL-LITE score (baseline)	74.0 ± 17.6	74.7 ± 16.2		74.2 ± 16.2
Change from baseline	10.2 ± 0.7	11.3 ± 0.7	0.221	12.6 ± 1.1	0.042
BDI-II score	4.0 ± 3.6	4.4 ± 4.3		4.1 ± 4.5
Change from baseline	−0.3 ± 0.3	−0.1 ± 0.3	0.669	−0.01 ± 0.5	0.630
BLOOM-DM completer population
IWQOL-LITE	73.5 ± 18.7	75.0 ± 16.2		76.0 ± 16.0		22
Change from baseline	10.8 ± 0.8	11.5 ± 0.8	0.482	13.2 ± 1.2	0.058
BDI-II	3.8 ± 3.5	4.3 ± 4.3		3.5 ± 3.5
Change from baseline	−0.5 ± 0.4	−0.6 ± 0.4	0.887	−0.6 ± 0.5	0.903

Notes:

* Compared between change in placebo group and change in intervention group; N/A group was not assessed in this trial.

Abbreviations: IWQOL-LITE, Impact of Weight on Quality of Life-Lite; BDI-II, Beck Depression Inventory-II; LOCF, last observation carried forward; ITT, intention-to-treat.